Get the Stockscreener App
1.19
0.85%
0.01
After Hours:
1.76
0.57
+47.90%
Biocardia Inc stock is traded at $1.19, with a volume of 16,081.
It is up +0.85% in the last 24 hours and down -5.56% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.18
Open:
$1.19
24h Volume:
16,081
Relative Volume:
0.24
Market Cap:
$13.02M
Revenue:
$3,000
Net Income/Loss:
$-8.23M
P/E Ratio:
-0.8436
EPS:
-1.4107
Net Cash Flow:
$-7.44M
1W Performance:
-1.65%
1M Performance:
-5.56%
6M Performance:
-23.72%
1Y Performance:
-41.95%
1-Day Range:
$1.1572
$1.20
1-Week Range:
$1.08
$1.25
52-Week Range:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.82 | 2.55B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.85 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.70 | 356.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.81 | 315.27M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
46.21 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
Investment Report: Can BioCardia Inc expand its profit marginsDay Trade & Safe Capital Growth Plans - baoquankhu1.vn
BioCardia (BCDA) price target decreased by 38.00% to 15.81 - MSN
Guidance Update: Can BioCardia Inc ride the EV waveMarket Risk Report & Daily Volume Surge Signals - baoquankhu1.vn
BCDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Surprises Report: Is BioCardia Inc in a long term uptrendTrade Performance Summary & Smart Money Movement Tracker - baoquankhu1.vn
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 earnings call transcript - MSN
BioCardia, Inc. (BCDA) stock price, news, quote and history - Yahoo Finance UK
BioCardia submits heart failure trial data to FDA By Investing.com - Investing.com Canada
BioCardia Requests FDA Meeting On Accelerated Approval For CardiAMP In Heart Failure - TradingView
BioCardia Requests FDA Meeting to Discuss Accelerated Approval for CardiAMP Cell Therapy System - geneonline.com
BioCardia submits heart failure trial data to FDA - Investing.com
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure - The Manila Times
BioCardia Submits CardiAMP HF Study Data to FDA, Plans Meeting for Accelerated Approval Discussion - Quiver Quantitative
Heart failure subgroup saw 47% lower cardiac death as BioCardia heads to FDA - Stock Titan
BioCardia Seeks Accelerated FDA Pathway for CardiAMP HF - TipRanks
BioCardia files FDA meeting request on accelerated approval for CardiAMP after CardiAMP HF data submission - TradingView
BioCardia (NASDAQ: BCDA) pursues FDA accelerated path for CardiAMP HF - Stock Titan
Revenue per share of BioCardia, Inc. – FWB:6JU0 - TradingView
Book value per share of BioCardia, Inc. – FWB:6JU0 - TradingView
Portfolio Shifts: Can BioCardia Inc expand its profit marginsQuarterly Earnings Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
Altman Peter, president of BioCardia, buys BCDA stock worth $1.1k - Investing.com UK
Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus
Altman Peter, president of BioCardia, buys BCDA stock worth $1.1k By Investing.com - za.investing.com
BioCardia (BCDA) CEO adds 900 shares in open‑market stock purchases - Stock Titan
Layoff Watch: Is BioCardia Inc in a long term uptrend2026 Trends & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript - insidermonkey.com
BioCardia, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
BioCardia, Inc. Reports 2026 Financial Results and CardiAMP Clinical Program Updates - Minichart
BioCardia (BCDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit - MSN
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... By GuruFocus - Investing.com Canada
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
BioCardia (BCDA) Highlights Clinical Progress and Financials in Q4 2025 - GuruFocus
BioCardia, Inc.: Advancing Cell Therapy Systems for Heart Failure and Cardiovascular Disease – Clinical Trials, FDA Approvals, and Business Strategies (2025) - Minichart
Earnings Call Summary | BioCardia(BCDA.US) Q4 2025 Earnings Conference - 富途牛牛
BioCardia, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCDA) 2026-03-24 - Seeking Alpha
Biocardia Inc's HF2 Trial Enrollment and Regulatory Timeline Claims Clash in 2025 Earnings Calls - Bitget
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress By Investing.com - Investing.com South Africa
BCDA: Phase III CardiAMP HF data support regulatory filings as financials remain stable and catalysts approach - TradingView
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress - Investing.com Canada
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - tradingview.com
BCDA: CardiAMP therapy advances toward regulatory approval with strong clinical data and stable finances - TradingView
BIOCARDIA ($BCDA) Releases Q4 2025 Earnings - Quiver Quantitative
BCDA: Positive clinical trial results and regulatory progress, but net loss widened to $8.2 million - TradingView
Q4 2025 BioCardia Inc Earnings Call Transcript - gurufocus.com
[10-K] BioCardia, Inc. Files Annua... - Stock Titan
BioCardia Reports 2025 Business Highlights and Financial Results - The Manila Times
BioCardia, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
BioCardia Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - The Manila Times
BioCardia, Inc. to Host Conference Call for 2025 Financial Results and Corporate Update on March 24, 2026 - Quiver Quantitative
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):